Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
This blog post is the fourth in a series on the new National Institute for Health and Care Excellence (NICE) health technology evaluation manual. Each post…
Including Carer Quality of Life in Health Technology Evaluation: Are We There Yet?
10 March 2022
Carer quality of life impacts can be included in health technology evaluations, however little guidance is provided. NICE considered providing more guidance as part of their…
No Smoking Day 2022: Reflecting on OHE Projections from 1994
9 March 2022
Since 1984, the UK’s second Wednesday of each March is NO SMOKING DAY (NSD). The NSD aims to encourage smokers who want to quit. In 2022,…
Rare Disease Day 2022
28 February 2022
World Rare Disease Day aims to raise awareness of rare diseases and the impact they can have on patients. This blog explores OHE’s contributions to research…
New NICE Manual for Health Technology Evaluations: A Critical Discussion on the Most Relevant Changes (or Lack Thereof)
23 February 2022
OHE opens a series of blog posts on the NICE new health technology evaluation manual. The blogs will provide a critical discussion around the topics, including the…
Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
1 June 2022
Gene therapies represent a new era of medicine, offering the potential for truly transformational health gains, and further benefits for society and health systems.
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies
1 January 2022
A paradigm shift is occurring in cancer care with the introduction of tumour-agnostic therapies, for which the indication is defined by the molecular signature of the…
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
As US policymakers consider the potential implications of the drug pricing reforms contained within the Build Back Better Act, OHE releases a critique of the Congressional Budget Office scoring, demonstrating that the estimates are highly uncertain and policymakers should exercise caution when relying upon them.
Opportunity Cost in Health Care: a Favourite Research Topic for OHE
23 November 2021
OHE’s Chris Sampson is leading a new Research Topic published in Frontiers in Health Services, titled ‘Opportunity Costs in Health Care: Cost-effectiveness Thresholds and Beyond’. The…